

Process on Corporate Responsibility in the field of Pharmaceuticals

Aurélie Vandeputte
European Commission
DG Enterprise and Industry
Food and healthcare industries, Biotechnology
12 October 2010



European Commission
Enterprise and Industry

Process on Corporate Responsibility in the field of Pharmaceuticals

- After G10 process and High Level Pharmaceutical Forum: Momentum for **collaborative initiatives**
- **Societal** and **Industrial** drivers
- From **projects to recommendations...** 2 years to deliver outside the regulatory decision making
- Competent authorities, public and private stakeholders:
 - Will be invited to become **members of the process**
 - Will be offered to participate in **projects on voluntary basis**

Areas of focus

- **Transparency and deontology** in the sector
- **Access to medicines in Africa**
- **Access to medicines in Europe**, in the context of pricing and reimbursement

Project on Transparency and Deontology

- To **exchange information** and potentially achieve a **common understanding** in terms of best practices when it comes to access to medicines:
 - Relation between industry and competent authorities
 - Relation between industry and healthcare professionals
 - Relation between industry and patients

Projects on Access in Africa

- Facilitate **reflection on the contribution of European companies**, their **added value** and the **challenges** they face.
- By looking at the needs of the concerned countries, the platform should **identify how stakeholders, and in particular industry, could contribute further.**

Platform Access to medicines in Europe

- Pharmaceutical pricing and reimbursement policies fall within the competence of Member States. The **principle of subsidiary** applies in this field and must be fully respected.
- The platform will be dedicated to **enhance collaboration** in order to find **common non-regulatory approaches** to ensure timely and equitable access to medicines after their marketing authorisation.

Structure - Platform Access to medicines in Europe

Steering Group

- To generate **momentum** for effective development of its projects and put **forward experienced-based recommendations**.
- **DG ENTR** will chair the group **in close collaboration with on going Presidencies** of the EU. The meetings could be organised in conjunction to the biannual meetings of the network of pricing and reimbursement authorities.

Projects

- for **concepts to be developed and tested**.
- Should focus on **concrete experiences** and will explore **non regulatory conditions for better access** to medicines after their marketing authorisation.
- The organisations will **volunteer experts**.

Members invited in the Platform Access to medicines in Europe

- ***Member States***

Relevant competent authorities of 27 Member States and EFTA countries

- ***Stakeholders from the public and private sectors***

- European Patients Forum – **EPF**
- Bureau Européen des Unions de Consommateurs - **BEUC**
- Standing Committee of European Doctors - **CPME**
- Pharmaceutical Group of the European Union – **PGEU**
- European Hospital and Healthcare Federation - **HOPE**
- Association Internationale de la Mutualité - **AIM**
- European Social Insurance Platform – **ESIP**

- European Federation of Pharmaceutical Industries & Associations - **EFPIA**
- European Generic medicines Association - **EGA**
- European Self-Medication Industry - **AESGP**
- European Association for Bioindustries - **EuropaBio**
- European Association of Full-Line Wholesalers – **GIRP**

Projects on Access in Europe

Encouraging access to innovative treatments

- Mechanism of **coordinated access to orphan medicinal products**
- Capacity building on **contractual agreements** for innovative medicines

Projects on Access in Europe

A responsible environment for access

- Facilitating the **supply in small countries**
- Promoting a **good governance for non- prescription drugs**
- Market access for **biosimilars**

This paper was produced for a meeting organized by Health & Consumers DG and represents the views of its author on the subject. These views have not been adopted or in any way approved by the Commission and should not be relied upon as a statement of the Commission's or Health & Consumers DG's views. The European Commission does not guarantee the accuracy of the data included in this paper, nor does it accept responsibility for any use made thereof.